GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Asset Turnover
Switch to:

OncoCyte (NAS:OCX) Asset Turnover

: 0.01 (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. OncoCyte's Revenue for the three months ended in Sep. 2022 was $1.02 Mil. OncoCyte's Total Assets for the quarter that ended in Sep. 2022 was $164.20 Mil. Therefore, OncoCyte's Asset Turnover for the quarter that ended in Sep. 2022 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. OncoCyte's annualized ROE % for the quarter that ended in Sep. 2022 was -45.26%. It is also linked to ROA % through Du Pont Formula. OncoCyte's annualized ROA % for the quarter that ended in Sep. 2022 was -22.74%.


OncoCyte Asset Turnover Historical Data

The historical data trend for OncoCyte's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.03 0.07

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 0.01

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte Asset Turnover Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Asset Turnover distribution charts can be found below:

* The bar in red indicates where OncoCyte's Asset Turnover falls in comparison to its industry or sector. The grey bar indicates the Asset Turnover's extreme value range as defined by GuruFocus.



OncoCyte Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

OncoCyte's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=7.727/( (55.419+159.563)/ 2 )
=7.727/107.491
=0.07

OncoCyte's Asset Turnover for the quarter that ended in Sep. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2022 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Sep. 2022 ))/ count )
=1.017/( (171.051+157.344)/ 2 )
=1.017/164.1975
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


OncoCyte  (NAS:OCX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

OncoCyte's annulized ROE % for the quarter that ended in Sep. 2022 is

ROE %**(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-37.332/82.477
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-37.332 / 4.068)*(4.068 / 164.1975)*(164.1975/ 82.477)
=Net Margin %*Asset Turnover*Equity Multiplier
=-917.7 %*0.0248*1.9908
=ROA %*Equity Multiplier
=-22.74 %*1.9908
=-45.26 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

OncoCyte's annulized ROA % for the quarter that ended in Sep. 2022 is

ROA %(Q: Sep. 2022 )
=Net Income/Total Assets
=-37.332/164.1975
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-37.332 / 4.068)*(4.068 / 164.1975)
=Net Margin %*Asset Turnover
=-917.7 %*0.0248
=-22.74 %

Note: The Net Income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


OncoCyte Asset Turnover Related Terms

Thank you for viewing the detailed overview of OncoCyte's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund director C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen officer: Chief Operating Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross officer: Chief Medical Officer 15 CUSHING, IRVINE CA 92618
Tony T Kalajian officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008

OncoCyte (NAS:OCX) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership